Program
Citrulline
Also written as “L-citrulline”, “L-citrulline tablets, 1000 mg” and “L-Citrulline”.
Its studies are mostly in Vaso-Occlusive Crises · Heart Septal Defects, Ventricular · Acute Lung Injury · Respiratory Insufficiency · Heart Septal Defects, Atrial, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Asklepion Pharmaceuticals | 71 open or running | phase 3since Jun 7, 2006 | Jun 7, 2006 | Jun 2027phase 3 · NCT06989567 |
| Angiogenix | 20 open or running | phase 2since Jul 10, 2006 | Jun 21, 2006 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jun 7, 2006First study: phase 3 study in Heart Defects, CongenitalNew to Asklepion PharmaceuticalsAsklepion Pharmaceuticals · NCT00335244 · 77 enrolled · United States
- Jun 21, 2006Angiogenix's first study: phase 1 study in Anemia, Sickle CellNew to AngiogenixAngiogenix · NCT00343954 · 12 enrolled · United States
- Jul 10, 2006Phase 2 study in Peripheral Arterial DiseaseAngiogenix · NCT00351286 · 160 enrolled · Russian Federation
- May 6, 2010Phase 2 study in Heart Septal Defects, AtrialAsklepion Pharmaceuticals · NCT01120964 · 22 enrolled · United States
- Aug 23, 2016Phase 3 study in Acute Lung InjuryAsklepion Pharmaceuticals · NCT02891837 · 189 enrolled · United States, Austria, Germany and more
- Sep 17, 2020Phase 2 study in Respiratory InsufficiencyAsklepion Pharmaceuticals · NCT04570384 · 65 enrolled · United States
- Mar 18, 2021Phase 2 study in Acute Vaso Occlusive Crisis (VOC)Asklepion Pharmaceuticals · NCT04852172 · 30 enrolled · United States
- Jan 24, 2022Phase 3 study in Heart Septal Defects, VentricularAsklepion Pharmaceuticals · NCT05253209 · 64 enrolled · United States
- May 8, 2025Phase 3 study in Anemia, Sickle CellAsklepion Pharmaceuticals · NCT06989567 · 120 planned · United States
Ahead
- Jun 2027Primary completion: phase 3 study in Anemia, Sickle CellAsklepion Pharmaceuticals · NCT06989567
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 9 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT06989567Anemia, Sickle Cell · United States | 3 | Not yet recruiting | Asklepion Pharmaceuticals | Jun 2027 | 120 |
| NCT05253209Heart Septal Defects, Ventricular · United States | 3 | Terminated | Asklepion Pharmaceuticals | May 10, 2024 | 64 |
| NCT04852172Acute Vaso Occlusive Crisis (VOC) · United States | 2 | Terminated | Asklepion Pharmaceuticals | Feb 29, 2024 | 30 |
| NCT04570384Respiratory Insufficiency · United States | 2 | Completed | Asklepion Pharmaceuticals | Aug 30, 2021 | 65 |
| NCT02891837Acute Lung Injury · United States, Austria, Germany and more | 3 | Completed | Asklepion Pharmaceuticals | Jun 2019 | 189 |
| NCT01120964Heart Septal Defects, Atrial · United States | 2 | Completed | Asklepion Pharmaceuticals | Apr 2012 | 22 |
| NCT00351286Peripheral Arterial Disease · Russian Federation | 2 | UNKNOWN | Angiogenix | 160 | |
| NCT00343954Anemia, Sickle Cell · United States | 1 | UNKNOWN | Angiogenix | 12 | |
| NCT00335244Heart Defects, Congenital · United States | 3 | Completed | Asklepion Pharmaceuticals | Dec 2009 | 77 |
How it is read
Names in the registry
- “L-citrulline”, 5 entries
- “L-citrulline tablets, 1000 mg”, 2 entries
- “L-Citrulline”, 1 entry
- “Intravenous L-Citrulline”, 1 entry
Conditions, from the studies’ own filings
- Vaso-Occlusive Crises, 2 studies
- Heart Septal Defects, Ventricular, 1 study
- Acute Lung Injury, 1 study
- Respiratory Insufficiency, 1 study
- Heart Septal Defects, Atrial, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.